We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Protein Atlas Accelerates Personalized Medicine in Leukemia Patients

By LabMedica International staff writers
Posted on 30 Apr 2019
Print article
Image: Blood film of a patient with acute myelogenous leukemia defined by presence of more than 90% myeloblasts in blood and/or bone marrow (Photo courtesy of Pathpedia).
Image: Blood film of a patient with acute myelogenous leukemia defined by presence of more than 90% myeloblasts in blood and/or bone marrow (Photo courtesy of Pathpedia).
Acute myelogenous leukemia is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis.

To improve that survival rate, scientists have created an online atlas to identify and classify protein signatures present at AML diagnosis. The new protein classifications will help clinicians recommend better treatment and personalized medicine for patients suffering from this aggressive cancer, which occurs in the blood and bone marrow.

A team of scientists at the University of Texas at San Antonio (UTSA, San Antonio, TX, USA) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA) examined the genetic, epigenetic and environmental diversity that occurs in cancerous cells due to AML. They analyzed proteomic screens of 205 patient biopsies and developed a new computational method called MetaGalaxy to categorize the protein signatures into 154 different patterns based on their cellular functions and pathways.

By approaching this challenge through the unique lens of developing a quantitative map for each leukemia patient from protein expression in their blood and bone marrow, rather than the standard lens of qualitative metrics and genetic risks alone, the collaborators will be able to more precisely categorize patients into risk groups and better predict their treatment outcomes. The team found 11 constellations of correlated functional patterns and 13 signatures that stratify the outcomes of patients. The scientists found limited overlap between proteomics data and both cytogenetics and genetic mutations. Moreover, leukemia cell lines show limited proteomic similarities with cells from patients with AML, suggesting that a deeper focus on patient-derived samples is needed to gain disease-relevant insights.

Amina Qutub, PhD, an associate professor and Biochemical Engineer and a senior study author said, “Acute myelogenous leukemia presents as a cancer so heterogeneous that it is often described as not one, but a collection of diseases. To decipher the clues found in proteins from blood and bone marrow of leukemia patients, we developed a new computer analysis, MetaGalaxy that identifies molecular hallmarks of leukemia. These hallmarks are analogous to the way constellations guide navigation of the stars: they provide a map to protein changes for leukemia.” The study was published on April 15, 2019, in the journal Nature Biomedical Engineering.

Related Links:
University of Texas at San Antonio
University of Texas MD Anderson Cancer Center

Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
Automated Nucleic Acid Extraction System
Chemistry Analyzer
Chemiluminescence Analyzer
DZ-Lite 3000 Plus

Print article



view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.